A next-generation obesity drug helped nearly half of trial participants shed at least 30 percent of their body weight, researchers reported at the American Diabetes Association's 2026 Scientific Sessions. The drug, retatrutide, already nicknamed the "Godzilla jab", also cut knee osteoarthritis pain by roughly 70 percent and improved markers of cardiovascular and metabolic health, according to findings from the TRIUMPH-1 trial.
But the same results fueling excitement in the medical community are also feeding a dangerous parallel market. Researchers tracking illicit drug sales say retatrutide was the most-listed GLP-1 product on the black market as far back as 2024, before it had even been licensed for use anywhere. Eli Lilly, the drugmaker behind both retatrutide and the blockbuster Mounjaro, is expected to seek regulatory approval to roll out the new drug in the United Kingdom within months.
The trial data, the black-market surge, and the regulatory timeline all converge at a moment when obesity treatment is becoming one of the most consequential, and most chaotic, corners of modern medicine.
The TRIUMPH-1 trial enrolled more than 2,300 participants. On the highest dose, patients lost an average of roughly 70 pounds, about 30 percent of their body weight, over the course of the study, the Daily Mail reported. Forty-five percent of patients hit the 30-percent threshold.
Those numbers dwarf what Mounjaro, already considered a powerful weight-loss treatment, delivers. Mounjaro helps users lose around 20.9 percent of their body weight over 72 weeks. Retatrutide's edge comes from its mechanism: it targets three hormone receptors linked to appetite, metabolism, and energy burn, compared to the two receptors that Mounjaro engages.
The weight loss alone would make headlines. But the trial also showed improvements beyond the scale. Researchers found retatrutide reduced knee osteoarthritis pain by approximately 70 percent, improved blood sugar control, and lowered cardiovascular risk factors. The drug showed potential to ease obstructive sleep apnoea as well, though the fact pack does not specify full data on that outcome.
Professor Ania Jastreboff of Yale School of Medicine, the trial's lead investigator, framed the results in clinical terms:
"Obesity is a chronic disease, and people living with obesity deserve treatment options that match the complex biology of their condition. Importantly, treatment with retatrutide not only resulted in robust weight loss, but also clear improvements in cardiometabolic health."
She added that people with severe obesity on the highest dose lost on average around 30 percent of their body weight. The broader health improvements, arthritis relief, better metabolic markers, cardiovascular gains, are what separate retatrutide from earlier-generation drugs that delivered weight loss alone.
The nation's chronic disease burden is not a new story. Robert F. Kennedy Jr. has made the case that America is "the sickest country in history" and called for overhauling federal dietary guidelines. A drug that tackles obesity and its downstream consequences, joint pain, heart disease, metabolic dysfunction, lands squarely in that conversation.
Retatrutide is not yet licensed. No pharmacy can legally dispense it. That hasn't slowed demand.
Dr. Luke Turnock, a senior lecturer in criminology at the University of Lincoln in the UK who monitors illegal drug sales, told the Daily Mail that retatrutide was the most-listed GLP-1 product on the illicit market back in 2024. Its popularity, he said, is growing alarmingly fast.
Dr. Luke Cox, a lecturer at Swansea University's school of sport and exercise science, worked closely with Turnock on a study published in April of this year examining how social media and internet forums fuel a false sense of confidence around counterfeit retatrutide, what researchers call "fake reta." Cox described an ecosystem in which social media influencers, funded through affiliate links to online shops, push the drug into the mainstream with little regard for safety.
Cox did not mince words about the state of the market:
"The rapid expansion of this market is scary. It's like the Wild West."
He warned of a "reliance on anecdotal expertise" and a "spread of misinformation, unsafe experimentation and exaggerated claims of efficacy" across online platforms. The picture he and Turnock paint is one in which consumers, desperate for results, are buying unregulated compounds from unverified sellers, often with no idea what they are actually injecting.
This is a pattern conservatives have seen before in other policy areas. When legitimate channels move slowly and demand runs hot, black markets fill the gap. The question is whether regulators can approve and distribute retatrutide fast enough to undercut the counterfeit trade, or whether bureaucratic timelines will leave patients exposed to dangerous knockoffs for months or years longer than necessary.
Dr. Simon Cork of Anglia Ruskin University offered a measured endorsement of the trial data:
"These results are incredibly promising and show we are moving closer to being able to effectively treat obesity with medication. The improvements in wider health measures are particularly encouraging."
Cork's emphasis on "wider health measures" matters. The obesity drug debate in the United States and the United Kingdom has often centered narrowly on weight loss, pounds dropped, waistlines shrunk. The TRIUMPH-1 data suggests retatrutide does something more: it addresses conditions that make obesity lethal, not just inconvenient. Joint pain that limits mobility. Cardiovascular risk factors that shorten lives. Metabolic dysfunction that drives diabetes.
Meanwhile, other chronic health threats continue to emerge across the population. Recent data show rectal cancer deaths climbing fast among younger Americans, a reminder that the country's health challenges extend well beyond obesity, even as obesity compounds many of them.
What the trial data does not yet show is equally important. Full long-term safety findings for retatrutide remain unclear from the available information. Common side effects included nausea, diarrhea, and vomiting, consistent with the GLP-1 drug class, but the depth of safety data beyond those basics is not detailed. The full trial design, dosing schedule, duration, and inclusion criteria are not specified either. Nor is it clear which specific regulatory body would review retatrutide for UK approval.
These are not trivial gaps. Any drug that produces this level of metabolic change will face intense scrutiny on long-term safety. The history of weight-loss drugs, from fen-phen to more recent controversies, should make regulators and patients cautious, even when the headline numbers look impressive.
Eli Lilly is expected to seek approval to roll out retatrutide in the UK within months. No timeline for a U.S. filing is specified in the available reporting. The company already markets Mounjaro, which targets two hormone receptors. Retatrutide's triple-agonist design, hitting a third receptor tied to energy burn, represents a meaningful step forward in the pharmacology, if the safety profile holds up under broader scrutiny.
The commercial stakes are enormous. The GLP-1 drug market has already reshaped pharmaceutical revenue, investor expectations, and patient behavior worldwide. A drug that outperforms Mounjaro on weight loss and delivers measurable improvements in arthritis, heart risk, and metabolic health would be a category leader almost immediately.
But the black-market problem is not going away on its own. As Cox and Turnock's research shows, the demand curve for retatrutide is already steep, and it is being serviced by sellers operating outside any regulatory framework. Every month that passes between the release of trial data and the granting of a license is another month in which consumers are buying unverified compounds online, guided by influencers with financial incentives to sell, not to inform.
This is where government has a clear role. Fast, rigorous review processes, not rubber stamps, but not bureaucratic paralysis either, serve patients and undercut black markets at the same time. The alternative is a growing population of self-medicating consumers injecting substances they bought from strangers on the internet.
The TRIUMPH-1 data is genuinely striking. A drug that helps patients lose 30 percent of their body weight, cuts arthritis pain by 70 percent, and improves cardiovascular markers addresses some of the most expensive and debilitating conditions in modern medicine. If the safety data holds, retatrutide could change the treatment landscape for millions.
But the same trial results that excite researchers are also accelerating a counterfeit market that puts patients at real risk. The gap between what science can deliver and what regulators allow patients to access is where the danger lives.
Good medicine that people can't legally get is an invitation for bad actors to fill the void. Regulators on both sides of the Atlantic would do well to remember that.
